Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared an announcement on LinkedIn:
”Primary immune thrombocytopenia (ITP) is a rare autoimmune blood disorder characterized by low platelet counts leading to an increased risk of bleeding, bruising and chronic fatigue. For many people living with ITP, chronic treatment can disrupt their daily life due to the burden of regular dosing, dose adjustments and side effects.
Today, we announced positive top-line results from our investigational treatment in primary ITP.
This marks our second positive data readout for this investigational asset as yesterday we announced positive Phase III results in Sjögren’s disease – reinforcing our efforts to addressing areas of high unmet needs across B-cell driven diseases.
With over two decades of experience advancing care in ITP, this milestone underscores our commitment to continuing to innovate with the aim of finding new and meaningful ways to improve patient outcomes.
I would like to extend my gratitude to the patients, families, and teams who made this possible as we reimagine medicine together.”
Read more about Shreeram Aradhye’s announcement here.
Stay updated on the latest breakthroughs in drug development with Hemostasis Today.
-
Mar 13, 2026, 22:57Robert Hamilton: The Reality of Stroke Care and Why 81.6% Should be a Wake-Up call
-
Mar 13, 2026, 22:05Christoph B. Olivier: Annabel Hölzle Shared Critical Findings on HALT After TAVR
-
Mar 13, 2026, 21:29Timothy Glidewell: Genetic Signals of Platelet and Clotting Pathways in Cryptogenic Stroke
-
Mar 13, 2026, 21:19New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
-
Mar 13, 2026, 21:01Leonardo Roever: Brain Age as a Biomarker of Neuroplasticity and Motor Recovery After Stroke
-
Mar 13, 2026, 20:50William Tembo: Understanding Stroke Through Landmark Clinical Trials
-
Mar 13, 2026, 20:35Jessica Garcia: New Evidence on Thrombin Generation Patterns in Children with Hemophilia A
-
Mar 13, 2026, 20:11Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
-
Mar 13, 2026, 19:53Wolfgang Miesbach Announces the New English Edition of “Gene Therapy Concepts in the Treatment of Haemophilia”